Technical Analysis for ROIV - Roivant Sciences Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | -0.73% | |
| Fell Below 20 DMA | Bearish | -0.73% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.73% | |
| 50 DMA Resistance | Bearish | -1.10% | |
| Crossed Above 20 DMA | Bullish | -1.10% | |
| Crossed Above 200 DMA | Bullish | -1.10% | |
| Stochastic Buy Signal | Bullish | -1.10% | |
| Up 3 Days in a Row | Strength | -1.10% | |
| Oversold Stochastic | Weakness | -1.10% | |
| 200 DMA Resistance | Bearish | 2.08% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 1 hour ago |
| 10 DMA Support | about 3 hours ago |
| 200 DMA Support | about 4 hours ago |
| Down 3% | about 4 hours ago |
| Fell Below 200 DMA | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/12/2024
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Autoimmune Disease Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Autoimmune Disease Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.24 |
| 52 Week Low | 8.06 |
| Average Volume | 7,566,186 |
| 200-Day Moving Average | 10.64 |
| 50-Day Moving Average | 10.94 |
| 20-Day Moving Average | 10.95 |
| 10-Day Moving Average | 10.74 |
| Average True Range | 0.38 |
| RSI (14) | 51.69 |
| ADX | 16.1 |
| +DI | 25.29 |
| -DI | 20.64 |
| Chandelier Exit (Long, 3 ATRs) | 10.65 |
| Chandelier Exit (Short, 3 ATRs) | 11.08 |
| Upper Bollinger Bands | 11.79 |
| Lower Bollinger Band | 10.11 |
| Percent B (%b) | 0.47 |
| BandWidth | 15.34 |
| MACD Line | -0.02 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0259 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.30 | ||||
| Resistance 3 (R3) | 11.30 | 11.18 | 11.23 | ||
| Resistance 2 (R2) | 11.18 | 11.08 | 11.17 | 11.21 | |
| Resistance 1 (R1) | 11.04 | 11.01 | 10.98 | 11.03 | 11.19 |
| Pivot Point | 10.91 | 10.91 | 10.88 | 10.91 | 10.91 |
| Support 1 (S1) | 10.77 | 10.81 | 10.71 | 10.77 | 10.61 |
| Support 2 (S2) | 10.65 | 10.75 | 10.64 | 10.59 | |
| Support 3 (S3) | 10.51 | 10.65 | 10.57 | ||
| Support 4 (S4) | 10.50 |
